Evaluation of nasal symptoms induced by platelet activating factor, after nasal challenge in both healthy and allergic rhinitis subjects pretreated with rupatadine, levocetirizine or placebo in a cross-over study design

Allergy, Asthma & Clinical Immunology

Rosa Muñoz-Cano³  Antonio Valero³  Ignacio Izquierdo²  Jaume Sánchez-López³  Alejandro Doménech⁴  Joan Bartra³  Joaquim Mullol¹  Cesar Picado³ 

[1] Unitat de Rinologia i Clinica de l’Olfacte, Servei d’Otorinolaringologia, Hospital Clínic, Barcelona, Catalonia, Spain

[2] J Uriach y Compañía, S.A., Poligono Industrial Riera de Caldes, Avinguda, Camí Reial, 51-57, 08184, Palau-Solità i Plegamans, Catalonia, Spain

[3] Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Catalonia, Spain

[4] Clinical Development Department, J Uriach y Compañia, S.A, Barcelona, Catalonia, Spain

关键词: Rupatadine;    Platelet activating factor;    Levocetirizine;    Healthy volunteers;    Antihistamines;    Allergic rhinitis;   

Others  :  792093
DOI  :  10.1186/1710-1492-9-43

 received in 2013-09-10, accepted in 2013-10-13,  发布年份 2013

【 摘 要 】

Background

Platelet-activating factor (PAF) is produced by most inflammatory cells and it is involved in inflammatory and allergic reactions. We aimed to assess the anti-PAF effects of rupatadine and levocetirizine in the upper airways.

Findings

Healthy volunteers (HV, N = 10) and seasonal allergic rhinitis (SAR, N = 10) asymptomatic patients were treated out of the pollen season with either rupatadine 20 mg, levocetirizine 10 mg, or placebo once a day during 5 days prior to the PAF nasal challenge. Total 4-nasal symptom score (T4SS) and nasal patency (Vol_2-5, by acoustic rhinometry) were assessed from 0 to 240 minutes after a repeated PAF challenge. In SAR patients but not in HV, both rupatadine and levocetirizine showed a trend to decrease PAF-induced T4SS from 60 to 120 minutes. Rupatadine but not levocetirizine caused a significant reduction (p < 0.05) of T4SS area under the curve compared to placebo. Rupatadine and levocetirizine caused no significant changes on nasal patency compared to placebo.

Conclusions

These results suggest that both rupatadine and levocetirizine showed a tendency decrease toward nasal symptoms, but only rupatadine significally reduces the overall nasal symptoms (AUC) induced by PAF in SAR patients.

【 授权许可】

   
2013 Muñoz-Cano et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Simons FE, Simons KJ: Histamine and H(1)-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011, 128(6):1139-1150. e4
• [2]Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, Garcia Rafanell J, Forn J: Rupatadine, a new potent, orally active dual antagonist of histamine and platelet activating factor (PAF). J Pharmacol Exp Ther 1997, 280:114-121.
• [3]Leggieri E, Tedeschi A, Lorini M, Bianco A, Miadonna A: Study of the effects of paf-acheter on human nasal airways. Allergy 1991, 6:466-471.
• [4]Tedeschi A, Palumbo G, Milazzo N, Miadonna A: Nasal neutrophilia and esosinophilia induced by challenge with platelet activating factor. J Allergy Clin Immunol 1994, 2:526-533.
• [5]Klementsson H, Andersson M: Eosinophil chemotactic activity of topical PAF on the human nasal mucosa. Eur J Clin Pharmacol 1992, 3:295-299.
• [6]Muñoz-Cano R, Valero A, Roca-Ferrer J, Bartra J, Sánchez-López J, Mullol J, Picado C: Platelet-activating factor nasal challenge induces nasal congestion and reduces nasal volume in both healthy volunteers and allergic rhinitis patients. Am J Rhinol Allergy 2013, 27:1-5.
• [7]Uzzaman A, Metcalfe DD, Komarow HD: Acoustic rhinometry in the practice of allergy. Ann Allergy Asthma Immunol 2006, 6:745-751.
• [8]Barrón S, Ramis I, García-Rafanell J, Merlos M: Inhibitory activity of rupatadine on pro-inflammatory cytokine production, relationship with binding affinity. Methods Find Exp Clin Pharmacol 2005, 27(2):161-162.
• [9]Queralt M, Merlos M, Giral M, Puigdemont A: Dual effect of a new compound, rupatadine, on edema induced by platelet activating factor and histamine in dogs: comparison with antihistamines and PAF antagonists. Drug Dev Res 1996, 39:12-18.
• [10]Church MK: Efficacy and tolerability of rupatadine at four times the recommended dose against histamine and PAF induced flare responses and ex vivo platelet aggregation in healthy males. Br J Dermatol 2010, 163(6):1330-1332.
• [11]Kajiwara N, Sasaki T, Bradding P, Cruse G, Sagara H, Ohmori K, Saito H, Ra C, Okayama Y: Activation of human mast cells thorough the patelet-activating factor receptor. J Allergy Clin Immunol 2010, 5:1137-1145. e1136
• [12]Tedeschi A, Milazzo N, Miadonna A: Nasal eosinophilia induced by PAF acether is accompanied by the release of eosinophil cationic protein. Eur Respir J 1994, 7(8):1445-1451.
• [13]Miadonna A, Tedeschi A, Arnoux B, Sala A, Zanussi C, Benveniste J: Evidence of PAF-acether metabolic pathway activation in antigen challenge of upper respiratory airways. Am Rev Respir Dis 1989, 140(1):142-147.
• [14]Maniscalco M, Sofia M, Faraone S, Carratu L: The effect of platelet-activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide. Allergy 2000, 55:757-761.
• [15]Greiner AN, Hellings PW, Rotiroti G, Scadding GK: Allergic rhinitis. Lancet 2011, 378(9809):2112-2122.
• [16]Maiti R, Rahman J, Jaida J, Allala U, Palani A: Rupatadine and levocetirizine for seasonal allergic rhinitis: a comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg 2010, 136(8):796-800.
• [17]Maiti R, Jaida J, Raghavendra B, Goud P, Ahmed I, Palani A: Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. J Drugs Dermatol 2011, 10(12):1444-1450.